On January 16, 2026, the U.S. Supreme Court announced its intent to hear the case of Hikma v. Amarin. This case follows the landmark GSK v. Teva ...

On August 22, 2024, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals, PLC (collectively Hikma), filed a petition for rehearing en banc, asking the US Court of Appeals for the Federal Circuit ...

Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its U.S. manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines ...

May 8 (Reuters) - Hikma Pharmaceuticals (HIK.L), opens new tab has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s ...

Hikma Pharmaceuticals USA has started work on a $1 billion investment that includes an expansion of its West Side facilities. The company, a division of London-based Hikma, officially broke ground ...

Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of progressive ...

AMMAN — Her Majesty Queen Rania visited Hikma Pharmaceuticals’ site in Al Salt on Monday, where she met with a number of its employees and learned more about the company’s initiatives in women ...

Hikma, a London-based generics maker, has agreed to buy parts of Xellia’s assets in the U.S., including the Danish drugmaker’s manufacturing facility in Cleveland. Hikma will pay $135 million in cash ...

Margin outlook for injectables unit lowered Overall 2025 forecasts maintained, including tariff impact First-half profit dips, but not as bad as analyst expectations Aug 7 (Reuters) - Hikma (HIK.L), ...

(RTTNews) - Shares of Hikma Pharmaceuticals PLC (HIK, HIK.L) were gaining around 4 percent in the early morning trading in London after the company on Thursday said it is confident of fiscal 2023, ...